Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors with PGA compounds

摘要

There is disclosed concomitant systemic administration of certain prostaglandins of the PGE-type and PGA-type, for example, 16,16-dimethyl-PGE2 of 16,16-dimethyl-PGA2, and a prostaglandin synthetase inhibitor, for example, indomethacin, aspirin, or phenylbutazone, to mammals, including humans. Thereby the undesirable gastrointestinal effects of the synthetase inhibitor are reduced.